JP2018521084A - 核酸ベースの治療法の標的送達の組成物 - Google Patents
核酸ベースの治療法の標的送達の組成物 Download PDFInfo
- Publication number
- JP2018521084A JP2018521084A JP2018503255A JP2018503255A JP2018521084A JP 2018521084 A JP2018521084 A JP 2018521084A JP 2018503255 A JP2018503255 A JP 2018503255A JP 2018503255 A JP2018503255 A JP 2018503255A JP 2018521084 A JP2018521084 A JP 2018521084A
- Authority
- JP
- Japan
- Prior art keywords
- composition
- scaffold
- cell
- fibril
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
- A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
- A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/22—Polypeptides or derivatives thereof, e.g. degradation products
- A61L27/24—Collagen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/14—Macromolecular materials
- A61L27/26—Mixtures of macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/54—Biologically active materials, e.g. therapeutic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/56—Porous materials, e.g. foams or sponges
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/258—Genetic materials, DNA, RNA, genes, vectors, e.g. plasmids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
- A61L2300/414—Growth factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
- A61L2300/62—Encapsulated active agents, e.g. emulsified droplets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/06—Flowable or injectable implant compositions
Abstract
【選択図】図5
Description
本願は、2015年7月24日に出願され、「核酸ベースの治療法の標的送達の組成物」と題された、米国仮特許出願第62/196,634号の利益及び優先権を主張し、その全体の開示が参照により本明細書に組み込まれる。
1.一般的にPEG、特にマルチアームPEGは、液晶状態に影響を及ぼさない。従って、全ての異なるパターン、特に、皮膚様パターン(skin−like)、配向的パターン(aligned)、配向的で織り込まれたパターン(aligned−braided)(米国特許8,492,332B2、8,227,574B2、及び8,513,382B2を参照)は、フィブリルコラーゲンを含む液晶材料から作ることができる。
2.材料堆積及びパターン形成の後、UV(例えば、マルチアームPEGの反応基次第で、250nm)により、膜を乾燥状態で架橋することができる。
応力(MPa)=10−6x 力(N)/面積(m2)
BioBridgeの機械測定を、目盛引張試験機により湿潤状態で行った。典型的な応力−変位曲線を図10に示す。従って、典型的な引っ張り強度は100gFより大きいため、最大応力は30MPa以上である。
Claims (20)
- 少なくとも1種類の細胞の付着及び配置を可能とする少なくとも1つの配向したフィブリル材を具える組成物であって、前記フィブリル材は、前記フィブリル材に付着した細胞の遺伝子発現を調節する核酸ベースの分子を具えることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記核酸ベースの分子は、前記フィブリル材に付着した細胞の遺伝子導入を可能とする核酸ベクターであることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記フィブリル材は、液晶材料を形成する自己組織化ポリペプチド、フィブリルポリペプチド、フィブリルコラーゲン、フィブリン、フィブロネクチン、ラミニン、シルク、ポリ‐L‐乳酸、ポリグリコール酸、エラスティン様ポリペプチド、ポリ(炭酸プロピレン)、キトサン、それらの誘導体、又はそれらの組み合わせの群から選択されることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記フィブリル材は、調節可能な分解速度を伴う生体適合性及び生分解性材料であることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記組成物は医療装置を更に具えることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記核酸は、pDNA、mRNA、miRNA、mmRNA、siRNA、RNAi、ssRNA、pDNA、dsRNA、アンチセンス、触媒RNA、及びそれらの誘導体の群から選択されることを特徴とする組成物。
- 請求項1に記載の組成物であって、核酸は、ポリマーナノ構造のカチオン性領域、又は、前記核酸と静電複合体を形成するカチオン性脂質及び/又はカチオン性ポリマーにより少なくとも部分的にカプセル化されることを特徴とする組成物。
- 請求項2に記載の組成物であって、化学的遺伝子導入法は静電相互作用に依存して、核酸を結合し、リン酸カルシウム、ポリカチオン、リポソーム、並びにカチオン性脂質、ポリマー、デンドリマー、ナノ粒子、ポリエチレンイミン、及びポリリジン等の化合物を用いる細胞膜を標的にすることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記核酸又は核酸ベースの化合物は、肝細胞、造血細胞、上皮細胞、内皮細胞、肺細胞、骨細胞、幹細胞、間葉細胞、神経細胞、心細胞、脂肪細胞、血管平滑筋細胞、心筋細胞、骨格筋細胞、膵ベータ細胞、下垂体細胞、滑膜ライニング細胞、卵巣細胞、精巣細胞、繊維芽細胞、B細胞、T細胞、網状赤血球、白血球、顆粒球、及び腫瘍細胞からなる群から選択される細胞の遺伝子発現を調節することを特徴とする組成物。
- 請求項1に記載の組成物であって、核酸ベースの分子は、アライメントシステムを用いて、注入により前記フィブリル材に担持されることを特徴とする組成物。
- 請求項1に記載の組成物であって、前記フィブリル材は、ポリ(エチレングリコール)、炭水化物、糖タンパク質、グリコサミノグリカン、単糖、多糖、又はそれらの組み合わせを更に具えることを特徴とする組成物。
- 請求項2に記載の組成物であって、前記配向したフィブリル材に付着した前記細胞への遺伝子導入は、組織培養用プラスチックに付着した同一の細胞への遺伝子導入よりも少なくとも60%多いことを特徴とする組成物。
- 糸状のフィブリルスキャフォールドを形成する組成物であって、前記フィブリルは、前記フィブリルが少なくとも1種類の細胞の付着及び配置を可能とするように、糸の方向に配向され、前記スキャフォールドは、前記フィブリルに付着した前記細胞の遺伝子発現を調節する核酸ベースの分子を具えることを特徴とする組成物。
- 請求項13に記載の組成物であって、前記糸状のスキャフォールドは、少なくとも80%が互いにつながった細孔を伴う多孔性を有し、前記スキャフォールドに沿ったキャピラリーフローを可能とし、前記スキャフォールドは少なくとも50ミクロンの直径、及び前記糸の方向に少なくとも20MPaの機械的強度を有することを特徴とする組成物。
- 請求項13に記載の組成物であって、前記スキャフォールドは、4週間から1年にわたる、架橋のレベルに応じた調節可能な分解を伴う生体適合性及び生分解性インプラントであることを特徴とする組成物。
- 請求項13に記載の組成物であって、前記スキャフォールドは、EDC/sNHSにより架橋された、配向した糸状のコラーゲンスキャフォールドであることを特徴とする組成物。
- 棒状のフィブリルマイクロキャリアを形成する組成物であって、前記フィブリルは、前記フィブリルが少なくとも1種類の細胞の付着及び配置を可能とするように、棒の方向に配向され、前記マイクロキャリアは、前記フィブリルに付着した前記細胞の遺伝子発現を調節する核酸ベースの分子を具えることを特徴とする組成物。
- 請求項17に記載の組成物であって、前記棒状のマイクロキャリアは、少なくとも80%が互いにつながった細孔を伴う多孔性を有し、前記マイクロキャリアに沿ったキャピラリーフローを可能とし、前記マイクロキャリアは少なくとも10ミクロンの直径、及び前記棒の方向に少なくとも20MPaの機械的強度を有することを特徴とする組成物。
- 請求項17に記載の組成物であって、前記マイクロキャリアは、4週間から1年にわたる、架橋のレベルに応じた調節可能な分解を伴う生体適合性及び生分解性インプラントであって、マイクロキャリアの水性の懸濁液が、注入可能な生体適合性及び生分解性スキャフォールドを形成することを特徴とする組成物。
- 請求項19に記載の組成物であって、前記マイクロキャリアは、EDC/sNHSにより架橋された、配向した棒状のコラーゲンスキャフォールドであることを特徴とする組成物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2021129887A JP2021185153A (ja) | 2015-07-24 | 2021-08-06 | 核酸ベースの治療法の標的送達の組成物 |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562196634P | 2015-07-24 | 2015-07-24 | |
US62/196,634 | 2015-07-24 | ||
PCT/US2016/043762 WO2017019568A1 (en) | 2015-07-24 | 2016-07-22 | Composition for targeted delivery of nucleic acid-based therapeutics |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021129887A Division JP2021185153A (ja) | 2015-07-24 | 2021-08-06 | 核酸ベースの治療法の標的送達の組成物 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2018521084A true JP2018521084A (ja) | 2018-08-02 |
Family
ID=57885295
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018503255A Pending JP2018521084A (ja) | 2015-07-24 | 2016-07-22 | 核酸ベースの治療法の標的送達の組成物 |
JP2021129887A Pending JP2021185153A (ja) | 2015-07-24 | 2021-08-06 | 核酸ベースの治療法の標的送達の組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2021129887A Pending JP2021185153A (ja) | 2015-07-24 | 2021-08-06 | 核酸ベースの治療法の標的送達の組成物 |
Country Status (4)
Country | Link |
---|---|
US (1) | US20180214575A1 (ja) |
JP (2) | JP2018521084A (ja) |
CN (1) | CN107849512B (ja) |
WO (1) | WO2017019568A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110499541B (zh) * | 2019-07-18 | 2021-09-14 | 福建农林大学 | 一种基于胶原液晶原位自组装的高强度仿生纤维及其制备方法 |
CN110496251B (zh) * | 2019-09-03 | 2022-04-01 | 上海微创医疗器械(集团)有限公司 | 阳离子纳米药物及其制备方法、载药植入医疗器械 |
JP7369951B2 (ja) | 2020-02-27 | 2023-10-27 | パナソニックIpマネジメント株式会社 | 表示モジュール |
AU2022228454A1 (en) * | 2021-03-01 | 2023-09-21 | Chelsea Bahney | Compositions comprising catenin mrna and their use for healing bone fractures |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
JP2010527637A (ja) * | 2006-12-05 | 2010-08-19 | コルエンジン,インク. | コラーゲン材料、フィルムおよびその製造方法 |
JP2012500203A (ja) * | 2008-08-11 | 2012-01-05 | フィブラリン コーポレイション | バイオコンポジット及びその製造方法 |
JP2012519537A (ja) * | 2009-03-04 | 2012-08-30 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 配向されたコラーゲンゲル |
WO2012114707A1 (ja) * | 2011-02-21 | 2012-08-30 | 株式会社アトリー | コラーゲン材料、及びコラーゲン材料の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2743139C (en) * | 2008-11-10 | 2019-04-02 | Alnylam Pharmaceuticals, Inc. | Novel lipids and compositions for the delivery of therapeutics |
US10238769B2 (en) * | 2011-10-11 | 2019-03-26 | Fibralign Corporation | Graft for directed vascular and lymphatic regeneration and methods to guide endothelial cell assembly |
AU2012352180A1 (en) * | 2011-12-16 | 2014-07-31 | Moderna Therapeutics, Inc. | Modified nucleoside, nucleotide, and nucleic acid compositions |
-
2016
- 2016-07-22 JP JP2018503255A patent/JP2018521084A/ja active Pending
- 2016-07-22 CN CN201680043462.9A patent/CN107849512B/zh active Active
- 2016-07-22 US US15/747,136 patent/US20180214575A1/en active Pending
- 2016-07-22 WO PCT/US2016/043762 patent/WO2017019568A1/en active Application Filing
-
2021
- 2021-08-06 JP JP2021129887A patent/JP2021185153A/ja active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001199903A (ja) * | 1999-11-09 | 2001-07-24 | Eizo Mori | 核酸含有複合体 |
JP2010527637A (ja) * | 2006-12-05 | 2010-08-19 | コルエンジン,インク. | コラーゲン材料、フィルムおよびその製造方法 |
JP2012500203A (ja) * | 2008-08-11 | 2012-01-05 | フィブラリン コーポレイション | バイオコンポジット及びその製造方法 |
JP2012519537A (ja) * | 2009-03-04 | 2012-08-30 | ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティ | 配向されたコラーゲンゲル |
WO2012114707A1 (ja) * | 2011-02-21 | 2012-08-30 | 株式会社アトリー | コラーゲン材料、及びコラーゲン材料の製造方法 |
Non-Patent Citations (1)
Title |
---|
BIOMATERIALS, vol. 34, JPN6021047530, 2013, pages 4038 - 4047, ISSN: 0004647149 * |
Also Published As
Publication number | Publication date |
---|---|
CN107849512A (zh) | 2018-03-27 |
WO2017019568A1 (en) | 2017-02-02 |
US20180214575A1 (en) | 2018-08-02 |
JP2021185153A (ja) | 2021-12-09 |
CN107849512B (zh) | 2023-01-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Gorain et al. | The use of nanoscaffolds and dendrimers in tissue engineering | |
Yu et al. | Electrospun PLGA fibers incorporated with functionalized biomolecules for cardiac tissue engineering | |
Martins et al. | Osteogenic induction of hBMSCs by electrospun scaffolds with dexamethasone release functionality | |
Wang et al. | Evaluation of the potential of rhTGF-β3 encapsulated P (LLA-CL)/collagen nanofibers for tracheal cartilage regeneration using mesenchymal stems cells derived from Wharton's jelly of human umbilical cord | |
Yu et al. | The use of human mesenchymal stem cells encapsulated in RGD modified alginate microspheres in the repair of myocardial infarction in the rat | |
JP2021185153A (ja) | 核酸ベースの治療法の標的送達の組成物 | |
Sang et al. | Biomimetic silk scaffolds with an amorphous structure for soft tissue engineering | |
Rujitanaroj et al. | Controlling fibrous capsule formation through long-term down-regulation of collagen type I (COL1A1) expression by nanofiber-mediated siRNA gene silencing | |
Rubert et al. | Electrospun PCL/PEO coaxial fibers for basic fibroblast growth factor delivery | |
Chen et al. | Promoting neurite growth and schwann cell migration by the harnessing decellularized nerve matrix onto nanofibrous guidance | |
Chen et al. | Self-assembled human adipose-derived stem cell-derived extracellular vesicle-functionalized biotin-doped polypyrrole titanium with long-term stability and potential osteoinductive ability | |
MX2008015695A (es) | Andamios biomimeticos biomolecula-enlazados. | |
Moradian et al. | Combining NT3-overexpressing MSCs and PLGA microcarriers for brain tissue engineering: a potential tool for treatment of Parkinson's disease | |
Liu et al. | Control of cell proliferation in E-jet 3D-printed scaffolds for tissue engineering applications: the influence of the cell alignment angle | |
Li et al. | Sustained release of plasmid DNA from PLLA/POSS nanofibers for angiogenic therapy | |
Li et al. | Poly (l-lactide-co-caprolactone) scaffolds enhanced with poly (β-hydroxybutyrate-co-β-hydroxyvalerate) microspheres for cartilage regeneration | |
Shi et al. | A protein/antibiotic releasing poly (lactic-co-glycolic acid)/lecithin scaffold for bone repair applications | |
Yu et al. | Progress in self-assembling peptide-based nanomaterials for biomedical applications | |
Zaitseva et al. | Aligned nanofibrillar scaffolds for controlled delivery of modified mRNA | |
Kim et al. | A cell-laden hybrid fiber/hydrogel composite for ligament regeneration with improved cell delivery and infiltration | |
John et al. | Tethering peptides onto biomimetic and injectable nanofiber microspheres to direct cellular response | |
Wen et al. | Design and characterization of core–shell mPEG–PLGA composite microparticles for development of cell–scaffold constructs | |
US20220331405A1 (en) | Aptamer assemblies for protein crosslinking | |
CN110565207B (zh) | 一种纤维材料及其制备方法和应用 | |
CN101500508A (zh) | 生物分子连接的仿生支架 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190710 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200630 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200707 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201002 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20201201 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210107 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20210406 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210806 |
|
C60 | Trial request (containing other claim documents, opposition documents) |
Free format text: JAPANESE INTERMEDIATE CODE: C60 Effective date: 20210806 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20210806 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20210915 |
|
C21 | Notice of transfer of a case for reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C21 Effective date: 20210921 |
|
A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20211203 |
|
C211 | Notice of termination of reconsideration by examiners before appeal proceedings |
Free format text: JAPANESE INTERMEDIATE CODE: C211 Effective date: 20211207 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20221129 |
|
C13 | Notice of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: C13 Effective date: 20230228 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230228 |
|
C22 | Notice of designation (change) of administrative judge |
Free format text: JAPANESE INTERMEDIATE CODE: C22 Effective date: 20230411 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230523 |